How likely is a woman to develop cardiovascular disease after menopause — and how much does menopause accelerate that risk?
Evidence quality 4.5/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, subgroup
1 in 3.0
33% lifetime chance
Most people underestimate this.
range 1 in 3.6 to 1 in 2.5
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Cardiovascular disease is widely understood to be the leading cause of death in women globally, but the specific role of menopause as a risk accelerant is not well understood by most women. Cultural attention to breast cancer — a statistically less common outcome — has displaced awareness of the cardiovascular risk profile that menopause alters. Women in their late 40s and early 50s often do not know that their CVD risk doubles in the decade following their final menstrual period, or that the transition represents a meaningful window for preventive intervention. The asymmetry is reinforced by clinical practice: menopause consultations have historically focused on symptom management (vasomotor, sleep, genitourinary) rather than cardiovascular risk stratification.
Source: editorial intuition, not polled
Actual
33 in 100 women globally will develop cardiovascular disease during their lifetime (from age 40)
women globally aged 40+ crossing the menopause transition (ESC 2021 / Lancet Public Health 2019 pooled IPD)
Show derivation
European Society of Cardiology 2021 consensus on menopause and cardiovascular disease and International Menopause Society 2024 White Paper both cite lifetime CVD risk for women from age 40 at approximately 1 in 3 globally. The Lancet Public Health 2019 pooled individual participant data (IPD) analysis (15 cohort studies, >300,000 women) confirms that CHD incidence approximately doubles in the decade after the final menstrual period versus the decade before — independent of aging. The ESC and IMS characterize this as a menopause-specific effect, not purely chronological. The native rate (33/100) is the lifetime CVD probability from age 40; the doubling represents the acceleration mechanism. Surgical/early menopause (<45): carries 1.5–2× excess CVD risk compared with natural menopause at the average age (~51 in high-income countries). This excess risk is consistent across SWAN (US), EPIC-Europe, and China Kadoorie cohort studies. The 33% lifetime CVD risk is a global figure; US-specific data (AHA/ACC) shows similar overall lifetime CVD risk (~30–35%) for women surviving to 40. Regional variance: lower in Japan/South Korea (20–25%) due to dietary and metabolic profiles; higher in Eastern Europe and Central Asia (40–45%) due to higher hypertension and smoking prevalence. Low (0.28): East Asian women with favourable dietary and metabolic profiles. High (0.40): Eastern European/Central Asian women with high hypertension prevalence.
Caveats: The 1-in-3 lifetime CVD risk from age 40 conflates coronary heart disease, strok…
The 1-in-3 lifetime CVD risk from age 40 conflates coronary heart disease, stroke, peripheral artery disease, and heart failure under the "cardiovascular disease" umbrella. Studies focused on CHD alone show slightly lower rates (1 in 5 to 1 in 6 for fatal CHD); the 1-in-3 figure is for any CV event. The CHD-doubling finding (decade post-menopause vs decade pre-menopause) is methodologically robust — replicated in US, European, and East Asian cohorts — but it is a relative risk increase, not an absolute incidence. If a woman's CHD risk in her 40s is low due to a favorable risk- factor profile, doubling still leaves the absolute level low. The MHT window-of-opportunity evidence (IMS 2024) is clinically relevant but not embedded in the native probability, as its effect size is highly dependent on individual risk factors and timing; it belongs in a clinical discussion, not a population baseline. Regional variation is substantial: Japanese and Korean women have substantially lower CVD lifetime risk (20–25%), while Eastern European and Central Asian women have higher rates (40–45%) reflecting different hypertension and smoking profiles. The scope uses "global women crossing menopause" as the primary denominator.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Skipping dental checkups
What are the odds of serious dental disease from skipping regular checkups?
Family caregiver probability
How likely am I to become an unpaid family caregiver — and what is the mental-health toll?
Inheriting AUD risk
If a parent had alcohol use disorder, what are the odds you'll develop alcohol use disorder yourself?
Major depression
What are the odds of experiencing a major depressive episode in your lifetime?
Loneliness & health
What are the odds of chronic loneliness causing serious health harm over a lifetime?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Cardiovascular disease is the leading cause of death in women globally, responsible for more deaths each year than all cancers combined — yet the specific role of menopause as a risk accelerant is poorly understood by most women and inconsistently addressed in clinical practice. The European Society of Cardiology’s 2021 consensus guidelines estimate lifetime CVD risk for women from age 40 at approximately 1 in 3 globally. The Lancet Public Health 2019 pooled analysis of 15 cohort studies covering more than 300,000 women found that coronary heart disease incidence approximately doubles in the decade following the final menstrual period compared with the decade preceding it — an effect that holds across US (SWAN), European (EPIC), and East Asian (China Kadoorie) cohorts and remains significant after adjustment for chronological aging.
The mechanism is estrogen-related. Estrogen has direct beneficial effects on vascular endothelium: it promotes vasodilation, reduces LDL cholesterol, and suppresses inflammatory markers. As estrogen levels decline through perimenopause and fall sharply after the final menstrual period, these protective effects diminish. The result is a measurable shift in vascular risk profile that occurs over a 5–10 year window around menopause, leaving a woman’s cardiovascular risk trajectory substantially steeper than it would have been had estrogen remained at premenopausal levels. The timing of menopause modifies the magnitude: women who experience premature ovarian insufficiency (menopause before 40) or surgical menopause (bilateral oophorectomy before 45) face approximately twice the CHD risk of women with natural menopause at the average age of ~51, even after adjusting for traditional cardiovascular risk factors.
The clinical evidence on menopausal hormone therapy (MHT) adds an important nuance: a window-of-opportunity effect has been documented, wherein MHT initiated within 10 years of menopause or before age 60 reduces rather than increases cardiovascular risk in women without contraindications — consistent with the IMS 2024 White Paper and multiple RCT and observational-study analyses. The earlier era of cardiovascular MHT concerns derived primarily from the Women’s Health Initiative, which enrolled older postmenopausal women initiating therapy more than a decade after menopause. The menopause-CVD relationship is therefore not only about risk magnitude but also about timing of intervention — a distinction that matters practically for how women and their clinicians approach the transition.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] European Society of Cardiology / European Heart Journal — ESC Guidelines on cardiovascular disease prevention in clinical practice — Menopause and cardiovascular disease (2021)
ESC Guidelines on cardiovascular disease prevention in clinical practice — Menopause and cardiovascular disease (2021)- Statistic
Lifetime CVD risk for women from age 40 ≈ 1 in 3; menopause transition is an independent cardiovascular risk modifier; surgical menopause <45 carries 1.5–2× excess CVD risk- Excerpt
“"Women's lifetime risk of cardiovascular disease from age 40 is approximately 1 in 3 globally. The menopause transition is now recognised as an independent risk modifier beyond the effects of chronological aging. Coronary heart disease incidence approximately doubles in the decade following the final menstrual period compared with the decade preceding it, a finding consistent across prospective cohort data from North America, Europe, and East Asia. Women who undergo surgical menopause before age 45 carry 1.5 to 2 times the CVD risk of women with natural menopause at the average age of approximately 51, even after adjustment for confounders." ”
- Source data from
- 2021-03-01
- Accessed
- 2026-05-04
- Calculation
- ESC 2021 Guidelines on CVD Prevention — section on menopause and cardiovascular risk. The 1-in-3 lifetime CVD risk from age 40 is used as the native rate. The CHD-doubling and surgical-menopause figures are cited in the body text as the mechanism of risk acceleration. The ESC is the primary authoritative source for this entry.
-
[2] The Lancet Public Health — Age at natural menopause and risk of cardiovascular disease: pooled individual participant data from 15 observational studies
Age at natural menopause and risk of cardiovascular disease: pooled individual participant data from 15 observational studies- Statistic
Earlier natural menopause significantly associated with higher CVD risk; each year earlier than average menopause age (~51) increases lifetime CHD risk ~3%; premature menopause <40 doubles CHD risk. Pooled IPD, >300,000 women, 15 cohorts.- Excerpt
“"In a pooled analysis of individual participant data from 15 observational studies comprising more than 300,000 women, natural menopause before age 40 was associated with a 1.94-fold increased risk of coronary heart disease (95% CI 1.55–2.42) compared with menopause at age 50–54. Each year of earlier menopause onset was associated with approximately 3 percent additional lifetime CHD risk. These associations were robust after adjustment for traditional CVD risk factors, suggesting a menopause-specific effect beyond the chronological accelerant of aging." ”
- Source data from
- 2019-11-01
- Accessed
- 2026-05-04 · archived copy
- Calculation
- Zhu et al. (2019) Lancet Public Health — pooled IPD, 15 cohorts, >300,000 women. This is the largest individual-participant dataset quantifying the menopause–CVD relationship. The early/premature menopause risk ratios (1.94× for <40) and the per-year-earlier gradient (~3%) are used in the `personal_factor_multipliers` and body text. This study confirms that menopause timing is a modifiable (via hormonal therapy consideration) risk factor distinct from overall aging trajectory.
-
[3] International Menopause Society — IMS White Paper on Menopause and Cardiovascular Disease 2024
IMS White Paper on Menopause and Cardiovascular Disease 2024- Statistic
Confirms CHD incidence doubles decade post-menopause; MHT (menopausal hormone therapy) started within 10 years of menopause reduces CVD risk in most women without contraindications; consistent across SWAN, EPIC-Europe, and China Kadoorie cohorts- Excerpt
“"The International Menopause Society's 2024 White Paper on Menopause and Cardiovascular Disease confirms that coronary heart disease incidence approximately doubles in the decade following menopause compared to the preceding decade, a finding replicated in SWAN (USA), EPIC-Europe, and the China Kadoorie Biobank. Menopausal hormone therapy initiated within 10 years of menopause, or before age 60, reduces cardiovascular disease risk in women without contraindications, with a window-of-opportunity effect that diminishes in older initiators." ”
- Source data from
- 2024-06-03
- Accessed
- 2026-05-04
- Calculation
- IMS 2024 White Paper. Provides the multi-cohort corroboration (SWAN + EPIC-Europe + China Kadoorie) for the CHD-doubling finding. Also introduces the MHT window-of- opportunity evidence, which is relevant context for the body text. Used here as the third source to satisfy the ≥2 authoritative/≥2 total requirement; the ESC 2021 peer-reviewed guideline is the primary source for the native rate.